JP2023537934A5 - - Google Patents
Info
- Publication number
- JP2023537934A5 JP2023537934A5 JP2023509394A JP2023509394A JP2023537934A5 JP 2023537934 A5 JP2023537934 A5 JP 2023537934A5 JP 2023509394 A JP2023509394 A JP 2023509394A JP 2023509394 A JP2023509394 A JP 2023509394A JP 2023537934 A5 JP2023537934 A5 JP 2023537934A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- composition
- target
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020902986A AU2020902986A0 (en) | 2020-08-21 | Peptides for Use in the Treatment or Prevention of Myocardial Damage | |
| AU2020902986 | 2020-08-21 | ||
| PCT/AU2021/050928 WO2022036411A1 (en) | 2020-08-21 | 2021-08-20 | Peptides for use in the treatment or prevention of myocardial damage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537934A JP2023537934A (ja) | 2023-09-06 |
| JP2023537934A5 true JP2023537934A5 (https=) | 2024-08-22 |
| JP7776492B2 JP7776492B2 (ja) | 2025-11-26 |
Family
ID=80322294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509394A Active JP7776492B2 (ja) | 2020-08-21 | 2021-08-20 | 心筋損傷の処置または防止に使用するためのペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240158447A1 (https=) |
| EP (1) | EP4200314A4 (https=) |
| JP (1) | JP7776492B2 (https=) |
| KR (1) | KR20230054440A (https=) |
| CN (1) | CN116615438A (https=) |
| AU (1) | AU2021327085A1 (https=) |
| CA (1) | CA3189838A1 (https=) |
| WO (1) | WO2022036411A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491523B2 (en) * | 2004-05-11 | 2009-02-17 | Hirsch Joel A | Voltage-dependent calcium channel beta subunit functional core |
| EP2173372B1 (en) * | 2007-06-18 | 2014-11-19 | Agency for Science, Technology and Research | Novel peptides and protein and uses thereof |
| WO2013113060A1 (en) * | 2012-01-31 | 2013-08-08 | The University Of Western Australia | Peptide |
| US11474098B2 (en) * | 2017-12-22 | 2022-10-18 | The Trustees Of Columbia University In The City Of New York | Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same |
-
2021
- 2021-08-20 CN CN202180051469.6A patent/CN116615438A/zh active Pending
- 2021-08-20 WO PCT/AU2021/050928 patent/WO2022036411A1/en not_active Ceased
- 2021-08-20 KR KR1020237009638A patent/KR20230054440A/ko active Pending
- 2021-08-20 US US18/043,880 patent/US20240158447A1/en active Pending
- 2021-08-20 AU AU2021327085A patent/AU2021327085A1/en active Pending
- 2021-08-20 EP EP21857054.7A patent/EP4200314A4/en active Pending
- 2021-08-20 CA CA3189838A patent/CA3189838A1/en active Pending
- 2021-08-20 JP JP2023509394A patent/JP7776492B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamashita et al. | A “second window of protection” occurs 24 h after ischemic preconditioning in the rat heart | |
| PH12021551341A1 (en) | Compositions for drg-specific reduction of transgene expression | |
| CL2021000550A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) | |
| AR126660A1 (es) | Mejorando la eficacia de la terapia génica dirigida a músculos | |
| JP2010512393A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| AR072610A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamacion | |
| RU2007136616A (ru) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина | |
| IE921935A1 (en) | Peptide derivatives of aollagenase inhibitor | |
| MY208862A (en) | Factor viii (fviii) gene therapy methods | |
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| RU2013127565A (ru) | Ингибиторы апоптоза и их применение | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| RU2019130941A (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
| DK2783697T3 (en) | VIP Fragments and uses thereof | |
| JP2023537934A5 (https=) | ||
| US5223485A (en) | Anaphylatoxin-receptor ligands | |
| RU2012108179A (ru) | Новый пептид и его применение | |
| EA030022B1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2020079489A2 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| JP2026062640A5 (https=) | ||
| WO2024081960A3 (en) | Methods to preserve and protect cardiomyocytes and reduce cardiac fibrosis following cardiac injury | |
| MX2023011875A (es) | Tratamiento genico para miocardiopatía arritmogénica del ventriculo derecho. | |
| Flindt-Hansen et al. | Wart treatment with anthralin | |
| Cichoń et al. | Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide |